Advertisement

CNS Drugs

, Volume 24, Issue 11, pp 909–927 | Cite as

The Pharmacoeconomics of Cognitive Enhancers in Moderate to Severe Alzheimer’s Disease

  • Jaclyn Cappell
  • Nathan Herrmann
  • Stephen Cornish
  • Krista L. LanctôtEmail author
Review Article

Abstract

Alzheimer’s disease is associated with a substantial economic impact on patients, their caregivers and society. Due to the current rise in the aging population, the prevalence and impact of Alzheimer’s disease are expected to increase greatly. The cost of caring for someone with Alzheimer’s disease is magnified in the more severe stages of the disease. There are four cognitive enhancers commonly used for the treatment of Alzheimer’s disease: three cholinesterase inhibitors (donepezil, rivastigmine and galantamine) and one NMDA receptor antagonist (memantine). Of these, donepezil and memantine have been approved in many countries as pharmacological treatments for moderate to severe Alzheimer’s disease, while donepezil, rivastigmine and galantamine are approved treatments for mild to moderate Alzheimer’s disease. While cost effectiveness has been well studied in mild to moderate Alzheimer’s disease, the cost-benefit information for drug therapy in moderate to severe Alzheimer’s disease is less clear. This article reviews the pharmacoeconomic data available on these four drugs, with a specific focus on moderate to severe Alzheimer’s disease, including economic burden, cost drivers, clinical outcomes and pharmacoeconomic studies. A key driver of the cost of Alzheimer’s disease is the severity of the disease, indicating that the ability to stabilize the disease state is a potential source of cost savings. Drug therapies that can limit increases in behavioural problems and cognitive and functional impairment, and postpone institutionalization without an increase in longevity may serve to reduce the economic burden on Alzheimer’s disease patients.

The data suggest that, while the available, approved agents offer only modest improvements in clinical outcomes, they could be cost-effective treatments for moderate to severe Alzheimer’s disease when viewed from the societal perspective. For memantine and donepezil, data are available that suggest that the cost of these drugs is offset by the clinical and societal benefits provided by slowing the progression of Alzheimer’s disease. While there are few head-to-head comparison trials, the similarity in costs of the treatments and efficacy against placebo suggest that cost effectiveness will not be substantially different among treatments. More studies that examine longitudinal resource utilization and its relationship to drug treatment in the moderate to severe stages are needed to clarify cost benefit in this population and possibly differentiate between individual medications.

Keywords

Memantine Rivastigmine Tacrine Galantamine Caregiver Burden 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The authors would like to acknowledge Impact Communication Partners, funded by Pfizer Inc., who provided an initial literature search and draft outline. No writing assistance was provided, and the authors contributed to the literature cited and modified the outline. The authors received no funding from Pfizer for writing this article.

None of the authors is an employee of Pfizer, Lundbeck, Janssen-Ortho or Novartis (the makers of the cholinesterase inhibitors and memantine in Canada) or a shareholder in these companies. Between them, Drs Herrmann and Lanctôt have received speakers’ honoraria and have participated in advisory boards for all four companies. Their research group has also received research support from Lundbeck and Janssen-Ortho in the past 5 years and Pfizer Inc. before that. Jaclyn Cappell and Stephen Cornish do not have any conflicts of interest to declare.

References

  1. 1.
    Wilcock GK, Ballard CG, Cooper JA, et al. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of 3 studies. J Clin Psychiatry 2008; 69(3): 341–8PubMedCrossRefGoogle Scholar
  2. 2.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Text revised. Washington, DC: American Psychiatric Association, 2000Google Scholar
  3. 3.
    Lopez OL, Becker JT, Sweet RA, et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 2003; 15(3): 346–53PubMedCrossRefGoogle Scholar
  4. 4.
    Brookmeyer R, Johnson E, Ziegler-Graham K, et al. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement 2007; 3(3): 186–91PubMedCrossRefGoogle Scholar
  5. 5.
    Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366(9503): 2112–7PubMedCrossRefGoogle Scholar
  6. 6.
    Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006; (1): CD005593Google Scholar
  7. 7.
    Herrmann N, Gauthier S. Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease. CMAJ 2008; 179(12): 1279–87Google Scholar
  8. 8.
    Farlow M, Anand R, Messina Jr J, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s disease. Eur Neurol 2000; 44(4): 236–41PubMedCrossRefGoogle Scholar
  9. 9.
    Feldman H, Gauthier S, Hecker J, et al. Efficacy and safety of donepezil in patients with more severe Alzheimer’s disease: a subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry 2005; 20(6): 559–69PubMedCrossRefGoogle Scholar
  10. 10.
    Craig D, Birks J. Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev 2006; (1): CD004746Google Scholar
  11. 11.
    Birks J, Grimley Evans J, Iakovidou V, et al. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev 2009; (2): CD001191Google Scholar
  12. 12.
    Voisin T, Vellas B. Diagnosis and treatment of patients with severe Alzheimer’s disease. Drugs Aging 2009; 26(2): 135–44PubMedCrossRefGoogle Scholar
  13. 13.
    Gauthier S, Scheltens P. Can we do better in developing new drugs for Alzheimer’s disease? Alzheimers Dement 2009 Nov; 5(6): 489–91PubMedCrossRefGoogle Scholar
  14. 14.
    Qaseem A, Snow V, Cross Jr JT, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008; 148(5): 370–8PubMedGoogle Scholar
  15. 15.
    Lyseng-Williamson KA, Plosker GL. Galantamine: a pharmacoeconomic review of its use in Alzheimer’s disease. Pharmacoeconomics 2002; 20(13): 919–42PubMedCrossRefGoogle Scholar
  16. 16.
    Neumann PJ, Hermann RC, Kuntz KM, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease. Neurology 1999; 52(6): 1138–45PubMedCrossRefGoogle Scholar
  17. 17.
    National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 111 (amended September 2007): donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer’s disease (amended). London: National Institute for Health and Clinical Excellence, 2007Google Scholar
  18. 18.
    Fagnani F, Lafuma A, Pechevis M, et al. Donepezil for the treatment of mild to moderate Alzheimer’s disease in France: the economic implications. Dement Geriatr Cogn Disord 2004; 17(1–2): 5–13PubMedCrossRefGoogle Scholar
  19. 19.
    Feldman HH, Pirttila T, Dartigues JF, et al. Treatment with galantamine and time to nursing home placement in Alzheimer’s disease patients with and without cerebrovascular disease. Int J Geriatr Psychiatry 2009; 24(5): 479–88PubMedCrossRefGoogle Scholar
  20. 20.
    Tampi RR, van Dyck CH. Memantine: efficacy and safety in mild-to-severe Alzheimer’s disease. Neuropsychiatr Dis Treat 2007; 3(2): 245–58PubMedCrossRefGoogle Scholar
  21. 21.
    Wimo A, Winblad B, Stoffler A, et al. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer’s disease. Pharmacoeconomics 2003; 21(5): 327–40PubMedCrossRefGoogle Scholar
  22. 22.
    Michaelis EK. Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging. Prog Neurobiol 1998; 54(4): 369–415PubMedCrossRefGoogle Scholar
  23. 23.
    McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006; (2): CD003154Google Scholar
  24. 24.
    [No authors listed]. FDA approves memantine drug for treating AD. Am J Alzheimers Dis Other Demen 2003 Nov–Dec; 18 (6): 329-30Google Scholar
  25. 25.
    Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev 2006; (1): CD001190Google Scholar
  26. 26.
    U.S. Food and Drug Administration. FDA approves expanded use of treatment for patients with severe Alzheimer’s disease [media release]: report no. P06-168, October 13, 2006 [online]. Available from URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108768.htm [Accessed 2010 Sep 3]
  27. 27.
    Homma A, Takeda M, Imai Y, et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer’s disease: a 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord 2000; 11(6): 299–313CrossRefGoogle Scholar
  28. 28.
    Blount PJ, Nguyen CD, McDeavitt JT. Clinical use of cholinomimetic agents: a review. J Head Trauma Rehabil 2002; 17(4): 314–21PubMedCrossRefGoogle Scholar
  29. 29.
    Loy C, Schneider L. Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev 2006; (1): CD001747Google Scholar
  30. 30.
    Seltzer B. Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease. Clin Interv Aging 5: 1-6Google Scholar
  31. 31.
    Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease: the Tacrine Study Group. JAMA 1994; 271(13): 985–91PubMedCrossRefGoogle Scholar
  32. 32.
    Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA 1994; 271(13): 992–8PubMedCrossRefGoogle Scholar
  33. 33.
    Hux MJ, O’Brien BJ, Iskedjian M, et al. Relation between severity of Alzheimer’s disease and costs of caring. CMAJ 1998; 159(5): 457–65PubMedGoogle Scholar
  34. 34.
    Small GW, McDonnell DD, Brooks RL, et al. The impact of symptom severity on the cost of Alzheimer’s disease. J Am Geriatr Soc 2002; 50(2): 321–7PubMedCrossRefGoogle Scholar
  35. 35.
    Wimo A, Winblad B, Jonsson L. The worldwide societal costs of dementia: estimates for 2009. Alzheimer Dement 2010; 6(2): 98–103CrossRefGoogle Scholar
  36. 36.
    Coduras A, Rabasa I, Frank A, et al. Prospective one-year cost-of-illness study in a cohort of patients with dementia of Alzheimer’s disease type in Spain: the ECO study. J Alzheimers Dis 2010; 19(2): 601–15PubMedGoogle Scholar
  37. 37.
    Jonsson L, Eriksdotter Jonhagen M, Kilander L, et al. Determinants of costs of care for patients with Alzheimer’s disease. Int J Geriatr Psychiatry 2006; 21(5): 449–59PubMedCrossRefGoogle Scholar
  38. 38.
    Wolstenholme J, Fenn P, Gray A, et al. Estimating the relationship between disease progression and cost of care in dementia. Br J Psychiatry 2002; 181: 36–42PubMedCrossRefGoogle Scholar
  39. 39.
    Allegri RF, Butman J, Arizaga RL, et al. Economic impact of dementia in developing countries: an evaluation of costs of Alzheimer-type dementia in Argentina. Int Psychogeriatr 2007; 19(4): 705–18PubMedCrossRefGoogle Scholar
  40. 40.
    Souetre E, Thwaites RM, Yeardley HL. Economic impact of Alzheimer’s disease in the United Kingdom: cost of care and disease severity for non-institutionalised patients with Alzheimer’s disease. Br J Psychiatry 1999; 174: 51–5PubMedCrossRefGoogle Scholar
  41. 41.
    Meserton J, Wimo A, By A, et al. Cross sectional observational study on the societal costs of Alzheimer’s disease. Curr Alzheimer Res 2010; 7(4): 358–67CrossRefGoogle Scholar
  42. 42.
    Lopez-Bastida J, Serrano-Aguilar P, Perestelo-Perez L, et al. Social-economic costs and quality of life of Alzheimer disease in the Canary Islands, Spain. Neurology 2006; 67(12): 2186–91PubMedCrossRefGoogle Scholar
  43. 43.
    Leon J, Cheng CK, Neumann PJ. Alzheimer’s disease care: costs and potential savings. Health Aff (Millwood) 1998; 17(6): 206–16CrossRefGoogle Scholar
  44. 44.
    Taylor Jr H, Schenkman M, Zhou J, et al. The relative effect of Alzheimer’s disease and related dementias, disability, and comorbidities on cost of care for elderly persons. J Gerontol B Psychol Sci Soc Sci 2001; 56(5): S285–93PubMedCrossRefGoogle Scholar
  45. 45.
    Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412–4PubMedCrossRefGoogle Scholar
  46. 46.
    Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12(3): 189–98PubMedCrossRefGoogle Scholar
  47. 47.
    Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc 1975; 23: 433–41PubMedGoogle Scholar
  48. 48.
    Bianchetti A, Castelletti F, Trabucchi M. Costs of dementia. Br J Psychiatry 2002; 181: 533–4PubMedCrossRefGoogle Scholar
  49. 49.
    Rigaud AS, Fagnani F, Bayle C, et al. Patients with Alzheimer’s disease living at home in France: costs and consequences of the disease. J Geriatr Psychiatry Neurol 2003; 16(3): 140–5PubMedCrossRefGoogle Scholar
  50. 50.
    Ernst RL, Hay JW, Fenn C, et al. Cognitive function and the costs of Alzheimer disease: an exploratory study. Arch Neurol 1997; 54(6): 687–93PubMedCrossRefGoogle Scholar
  51. 51.
    Beeri MS, Werner P, Davidson M, et al. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer’s disease patients. Int J Geriatr Psychiatry 2002; 17(5): 403–8PubMedCrossRefGoogle Scholar
  52. 52.
    Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994 Dec; 44(12): 2308–14PubMedCrossRefGoogle Scholar
  53. 53.
    Herrmann N, Lanctot KL, Sambrook R, et al. The contribution of neuropsychiatric symptoms to the cost of dementia care. Int J Geriatr Psychiatry 2006; 21(10): 972–6PubMedCrossRefGoogle Scholar
  54. 54.
    Tariot PN. Medical management of advanced dementia. J Am Geriatr Soc 2003; 51(5 Suppl. Dementia): S305–13PubMedCrossRefGoogle Scholar
  55. 55.
    Hill J, Fillit H, Thomas SK, et al. Functional impairment, healthcare costs and the prevalence of institutionalisation in patients with Alzheimer’s disease and other dementias. Pharmacoeconomics 2006; 24(3): 265–80PubMedCrossRefGoogle Scholar
  56. 56.
    Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J 1965; 14: 61–5PubMedGoogle Scholar
  57. 57.
    Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968 Jul; 114(512): 797–811PubMedCrossRefGoogle Scholar
  58. 58.
    Zhu CW, Scarmeas N, Torgan R, et al. Clinical features associated with costs in early AD: baseline data from the Predictors Study. Neurology 2006; 66(7): 1021–8PubMedCrossRefGoogle Scholar
  59. 59.
    Neumann PJ, Araki SS, Arcelus A, et al. Measuring Alzheimer’s disease progression with transition probabilities: estimates from CERAD. Neurology 2001; 57(6): 957–64PubMedCrossRefGoogle Scholar
  60. 60.
    Hebert R, Dubois MF, Wolfson C, et al. Factors associated with long-term institutionalization of older people with dementia: data from the Canadian Study of Health and Aging. J Gerontol A Biol Sci Med Sci 2001; 56(11): M693–9PubMedCrossRefGoogle Scholar
  61. 61.
    Fillit H, Hill J. Economics of dementia and pharmacoeconomics of dementia therapy. Am J Geriatr Pharmacother 2005; 3(1): 39–49PubMedCrossRefGoogle Scholar
  62. 62.
    Feldman HH, Pirttila T, Dartigues JF, et al. Analyses of mortality risk in patients with dementia treated with galantamine. Acta Neurol Scand 2009; 119(1): 22–31PubMedCrossRefGoogle Scholar
  63. 63.
    Winblad B, Black SE, Homma A, et al. Donepezil treatment in severe Alzheimer’s disease: a pooled analysis of three clinical trials. Curr Med Res Opin 2009; 25(11): 2577–87PubMedGoogle Scholar
  64. 64.
    Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 2009; 80(6): 600–7PubMedCrossRefGoogle Scholar
  65. 65.
    Lopez-Pousa S, Olmo JG, Franch JV, et al. Comparative analysis of mortality in patients with Alzheimer’s disease treated with donepezil or galantamine. Age Ageing 2006; 35(4): 365–71PubMedCrossRefGoogle Scholar
  66. 66.
    Gasper MC, Ott BR, Lapane KL. Is donepezil therapy associated with reduced mortality in nursing home residents with dementia? Am J Geriatr Pharmacother 2005; 3(1): 1–7PubMedCrossRefGoogle Scholar
  67. 67.
    Langa KM, Chernew ME, Kabeto MU, et al. National estimates of the quantity and cost of informal caregiving for the elderly with dementia. J Gen Intern Med 2001; 16(11): 770–8PubMedCrossRefGoogle Scholar
  68. 68.
    Fraser M, Snyder E. The economic benefits of delaying progression AD using cholinesterase inhibitors. Clin Geriatr 2000; 8: 72–93Google Scholar
  69. 69.
    Sink KM, Covinsky KE, Barnes DE, et al. Caregiver characteristics are associated with neuropsychiatric symptoms of dementia. J Am Geriatr Soc 2006; 54(5): 796–803PubMedCrossRefGoogle Scholar
  70. 70.
    Koppel R. Alzheimer’s disease: the costs to US businesses in 2002. Wyncote (PA): Social Research Corporation and Department of Sociology, University of Pennsylvania, 2002Google Scholar
  71. 71.
    Emre M, Mecocci P, Stender K. Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer’s disease. J Alzheimers Dis 2008; 14(2): 193–9PubMedGoogle Scholar
  72. 72.
    Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008; 148(5): 379–97PubMedGoogle Scholar
  73. 73.
    Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer’s disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry 2008; 23(5): 537–45PubMedCrossRefGoogle Scholar
  74. 74.
    Hansen RA, Gartlehner G, Webb AP, et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging 2008; 3(2): 211–25PubMedGoogle Scholar
  75. 75.
    Ferris S, Ihl R, Robert P, et al. Treatment effects of memantine on language in moderate to severe Alzheimer’s disease patients. Alzheimers Dement 2009; 5(5): 369–74PubMedCrossRefGoogle Scholar
  76. 76.
    Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003; 348(14): 1333–41PubMedCrossRefGoogle Scholar
  77. 77.
    Van Dyck CH, Tariot PN, Meyers B, et al. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 2007; 21(2): 136–43PubMedCrossRefGoogle Scholar
  78. 78.
    Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001; 57(4): 613–20PubMedCrossRefGoogle Scholar
  79. 79.
    Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006; 367(9516): 1057–65PubMedCrossRefGoogle Scholar
  80. 80.
    Homma A, Imai Y, Tago H, et al. Donepezil treatment of patients with severe Alzheimer’s disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord 2008; 25(5): 399–407PubMedCrossRefGoogle Scholar
  81. 81.
    Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007; 69(5): 459–69PubMedCrossRefGoogle Scholar
  82. 82.
    Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year period. Curr Med Res Opin 2005;21(8): 1317–27PubMedCrossRefGoogle Scholar
  83. 83.
    Dantoine T, Auriacombe S, Sarazin M, et al. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer’s disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract 2006; 60(1): 110–8PubMedCrossRefGoogle Scholar
  84. 84.
    Burns A, Bernabei R, Bullock R, et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer’s disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurol 2009; 8(1): 39–47PubMedCrossRefGoogle Scholar
  85. 85.
    Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291(3): 317–24PubMedCrossRefGoogle Scholar
  86. 86.
    Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease: the Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11 Suppl. 2: S33–9PubMedCrossRefGoogle Scholar
  87. 87.
    Schneider LS, Olin JT. Clinical global impressions in Alzheimer’s clinical trials. Int Psychogeriatr 1996; 8(2): 277–88; discussion 288-90PubMedCrossRefGoogle Scholar
  88. 88.
    Delis DC, Kaplan E, Kramer JH. The Delis-Kaplan executive function system: technical manual. San Antonio (TX): The Psychological Corporation, 2001Google Scholar
  89. 89.
    Reisberg B, Ferris SH, De Leon MJ, et al. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136–9PubMedGoogle Scholar
  90. 90.
    Carpenter GI, Hastie CL, Morris JN, et al. Measuring change in activities of daily living in nursing home residents with moderate to severe cognitive impairment. BMC Geriatr 2006; 6: 7PubMedCrossRefGoogle Scholar
  91. 91.
    Panisset M, Roudier M, Saxton J, et al. Severe impairment battery: a neuropsychological test for severely demented patients. Arch Neurol 1994 Jan; 51(1): 41–5PubMedCrossRefGoogle Scholar
  92. 92.
    Winblad B, Jones RW, Wirth Y, et al. Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007; 24(1): 20–7PubMedCrossRefGoogle Scholar
  93. 93.
    Reisberg B, Doody R, Stoffler A, et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006; 63(1): 49–54PubMedCrossRefGoogle Scholar
  94. 94.
    Wilkinson D, Andersen HF. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer’s disease. Dement Geriatr Cogn Disord 2007; 24(2): 138–45PubMedCrossRefGoogle Scholar
  95. 95.
    Feldman HH, Schmitt FA, Olin JT. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord 2006; 20(4): 263–8PubMedCrossRefGoogle Scholar
  96. 96.
    Plosker GL, Lyseng-Williamson KA. Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer’s disease. Pharmacoeconomics 2005; 23(2): 193–206PubMedCrossRefGoogle Scholar
  97. 97.
    Francois C, Sintonen H, Sulkava R, et al. Cost effectiveness of memantine in moderately severe to severe Alzheimer’s disease: a Markov model in Finland. Clin Drug Investig 2004; 24(7): 373–84PubMedCrossRefGoogle Scholar
  98. 98.
    Jones RW, McCrone P, Guilhaume C. Cost effectiveness of memantine in Alzheimer’s disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging 2004; 21(9): 607–20PubMedCrossRefGoogle Scholar
  99. 99.
    Rive B, Grishchenko M, Guilhaume-Goulant C, et al. Cost effectiveness of memantine in Alzheimer’s disease in the UK. J Med Econ 2010; 13(2): 371–80PubMedCrossRefGoogle Scholar
  100. 100.
    Antonanzas F, Rive B, Badenas JM, et al. Cost-effectiveness of memantine in community-based Alzheimer’s disease patients: an adaptation in Spain. Eur J Health Econ 2006; 7(2): 137–44PubMedCrossRefGoogle Scholar
  101. 101.
    Jonsson L. Cost-effectiveness of memantine for moderate to severe Alzheimer’s disease in Sweden. Am J Geriatr Pharmacother 2005; 3(2): 77–86PubMedCrossRefGoogle Scholar
  102. 102.
    Gagnon M, Rive B, Hux M, et al. Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada. Can J Psychiatry 2007; 52(8): 519–26PubMedGoogle Scholar
  103. 103.
    Livingston G, Katona C, Roch B, et al. A dependency model for patients with Alzheimer’s disease: its validation and relationship to the costs of care: the LASER-AD Study. Curr Med Res Opin 2004; 20(7): 1007–16PubMedCrossRefGoogle Scholar
  104. 104.
    Feldman H, Gauthier S, Hecker J, et al. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology 2004; 63(4): 644–50PubMedCrossRefGoogle Scholar
  105. 105.
    Marin D, Amaya K, Casciano R, et al. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer’s disease. Int Psychogeriatr 2003; 15(4): 385–98PubMedCrossRefGoogle Scholar
  106. 106.
    Weycker D, Taneja C, Edelsberg J, et al. Cost-effectiveness of memantine in moderate-to-severe Alzheimer’s disease patients receiving donepezil. Curr Med Res Opin 2007; 23(5): 1187–97PubMedCrossRefGoogle Scholar
  107. 107.
    Wimo A, Winblad B, Jonsson L. An estimate of the total worldwide societal costs of dementia in 2005. Alzheimers Dement 2007; 3(2): 81–91PubMedCrossRefGoogle Scholar
  108. 108.
    Fillit H, Gutterman EM, Lewis B. Donepezil use in managed Medicare: effect on health care costs and utilization. Clin Ther 1999; 21(12): 2173–85PubMedCrossRefGoogle Scholar
  109. 109.
    Wimo A, Winblad B. Economic aspects on drug therapy of dementia. Curr Pharm Des 2004; 10(3): 295–301PubMedCrossRefGoogle Scholar
  110. 110.
    Murman DL. The costs of caring: medical costs of Alzheimer’s disease and the managed care environment. J Geriatr Psychiatry Neurol 2001; 14(4): 168–78PubMedCrossRefGoogle Scholar
  111. 111.
    Leung GM, Yeung RY, Chi I, et al. The economics of Alzheimer disease. Dement Geriatr Cogn Disord 2003; 15(1): 34–43PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Jaclyn Cappell
    • 1
  • Nathan Herrmann
    • 1
  • Stephen Cornish
    • 1
  • Krista L. Lanctôt
    • 1
    Email author
  1. 1.Department of PsychiatrySunnybrook Health Sciences CentreTorontoCanada

Personalised recommendations